Clinical Research Directory
Browse clinical research sites, groups, and studies.
Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)
Sponsor: Valneva Austria GmbH
Summary
In this open-label Phase 3b, single arm trial, persistence of antibodies and long term safety will be evaluated in up to 375 participants rolled over from trial VLA1553-301 (NCT number: NCT04546724).
Official title: An Open-Label, Single Arm Trial To Evaluate Antibody Persistence And Long Term Safety Of A Live-Attenuated Chikungunya Virus Vaccine (VLA1553) In Adults Aged 18 Years and Above
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
363
Start Date
2021-04-02
Completion Date
2031-05
Last Updated
2025-12-24
Healthy Volunteers
Yes
Conditions
Interventions
VLA1553
Trial participants previously vaccinated with VLA1553 in trial VLA1553-301 will be followed up for safety and immunogenicity.
Locations (10)
Accelerated Enrollment Solutions (AES)
Phoenix, Arizona, United States
Velocity Clinical Research
Hallandale, Florida, United States
Accelerated Enrollment Solutions (AES)
Chicago, Illinois, United States
Alliance for Multispecialty Research (AMR)
Lexington, Kentucky, United States
Velocity Clinical Research
Grand Island, Nebraska, United States
Velocity Clinical Research
Omaha, Nebraska, United States
Alliance for Multispecialty Research (AMR)
Knoxville, Tennessee, United States
Velocity Clinical Research
Austin, Texas, United States
Velocity Clinical Research
West Jordan, Utah, United States
Allliance for Multispecialty Research (AMR)
Norfolk, Virginia, United States